Download the app
App StorePlay Store
Beige
Login
← All tags

pharmaceuticals

Quadria Capital and PE funds reportedly eye majority stake in Samarth Lifesciences at Rs 4500 crore valuation

Quadria Capital and PE funds reportedly eye majority stake in Samarth Lifesciences at Rs 4500 crore valuation

Quadria Capital is reportedly in talks to acquire a majority stake in Samarth Lifesciences, with the deal potentially valuing the company at about Rs 4,500 crore. The pharma firm is seeking fresh investment to support growth plans after earlier negotiations with alternative investors broke down due to mismatches in price expectations.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Sun Pharma FDA nod for Leqselvi as alopecia drug fight heats up against Pfizer and Eli Lilly

Sun Pharma FDA nod for Leqselvi as alopecia drug fight heats up against Pfizer and Eli Lilly

Sun Pharma’s big US bet is paying off. After spending over INR 4,688 crore to buy Concert Pharma, the company secured rights to Leqselvi for hair growth in alopecia areata patients. The drug has now received US FDA approval, but insiders say the real contest with global giants like Pfizer and Eli Lilly is only beginning.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Your news, in seconds

App StorePlay Store
Granules to tighten oversight after US FDA warning as revenue dependence on US looms

Granules to tighten oversight after US FDA warning as revenue dependence on US looms

Drugmaker Granules says it will tighten internal oversight following a warning from the US FDA. The company, one of the world’s biggest paracetamol makers and a key active pharmaceutical ingredients player, earns a large share of revenue from the United States—making compliance scrutiny especially consequential for future supply and sales.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Granules to tighten oversight after US FDA warning as it digitizes records and boosts compliance controls

Granules to tighten oversight after US FDA warning as it digitizes records and boosts compliance controls

Granules India says it will strengthen its manufacturing oversight after a US FDA warning related to documentation practices and contamination concerns. The company plans to digitize workflows and automate record management to improve data accuracy and compliance. Granules is positioning the reforms as proactive steps to address regulatory pressure while maintaining product quality across its facilities.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Sun Pharma wins Bombay High Court trademark fight banning Absun and Absun Pharma in decade dispute

Sun Pharma wins Bombay High Court trademark fight banning Absun and Absun Pharma in decade dispute

The Bombay High Court has barred a Navi Mumbai drugmaker from using the brand names “Absun” and “Absun Pharma,” siding with Sun Pharmaceutical Industries. In a long-running trademark dispute, the court ruled the competing names are deceptively similar to Sun Pharma’s established marks, potentially confusing consumers. The verdict effectively ends the decade-long legal battle.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Centre seeks methanol for pharma as West Asia disruptions shake global supplies

Centre seeks methanol for pharma as West Asia disruptions shake global supplies

The Centre is in discussions with Assam Petrochemicals and GNFC to secure methanol supply for India’s pharmaceutical sector. With West Asia-linked disruptions hitting global supply chains, officials are also focusing on logistics and distribution to prevent shortages. The move aims to stabilize availability of a key input for pharma production even as shipping and regional flows remain uncertain.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
Drug regulator reshuffles 95 officials across India to tighten compliance faster

Drug regulator reshuffles 95 officials across India to tighten compliance faster

India’s drug regulator, the Central Drugs Standard Control Organisation, has transferred about 95 officials across states as part of a structured policy. The stated goal is to strengthen compliance in the pharmaceutical sector and reduce the influence of long-serving officers. Officials say the reshuffle is intended to refresh oversight and improve how rules are enforced nationwide.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play